These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34624095)

  • 1. The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants.
    Rohrig A; Eyal N
    J Infect Dis; 2022 Mar; 225(6):934-937. PubMed ID: 34624095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccines: ethical framework concerning human challenge studies.
    Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
    Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.
    Steel R; Buchak L; Eyal N
    J Med Ethics; 2020 Dec; 46(12):808-812. PubMed ID: 32661074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
    Bui NN; Lin YT; Huang SH; Lin CW
    Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure.
    Eyal N; Lipsitch M
    Clin Microbiol Infect; 2021 Mar; 27(3):372-377. PubMed ID: 33421580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novavax offers first evidence that COVID vaccines protect people against variants.
    Callaway E; Mallapaty S
    Nature; 2021 Feb; 590(7844):17. PubMed ID: 33510489
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19: vaccination problems.
    Brüssow H
    Environ Microbiol; 2021 Jun; 23(6):2878-2890. PubMed ID: 33928745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Challenge Experiments in Nonhuman Primates: An Ethical Perspective.
    DeGrazia D; Miller FG
    Clin Infect Dis; 2021 Dec; 73(11):2121-2125. PubMed ID: 33786589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants.
    Su S; Shao Y; Jiang S
    Emerg Microbes Infect; 2021 Dec; 10(1):439-441. PubMed ID: 33635184
    [No Abstract]   [Full Text] [Related]  

  • 15. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.
    Behr MA; Divangahi M; Schurr E
    J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to redesign COVID vaccines so they protect against variants.
    Callaway E; Ledford H
    Nature; 2021 Feb; 590(7844):15-16. PubMed ID: 33514888
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies.
    Steuwer B; Jamrozik E; Eyal N
    Int J Infect Dis; 2021 Apr; 105():307-311. PubMed ID: 33592338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.